RCKT Relative Valuation
RCKT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RCKT is overvalued; if below, it's undervalued.
Historical Valuation
Rocket Pharmaceuticals Inc (RCKT) is now in the Fair zone, suggesting that its current forward PS ratio of 438.28 is considered Fairly compared with the five-year average of -8.31. The fair price of Rocket Pharmaceuticals Inc (RCKT) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：3.09
Fair
-1.68
PE
1Y
3Y
5Y
Trailing
Forward
-0.30
EV/EBITDA
Rocket Pharmaceuticals Inc. (RCKT) has a current EV/EBITDA of -0.30. The 5-year average EV/EBITDA is -7.39. The thresholds are as follows: Strongly Undervalued below -17.82, Undervalued between -17.82 and -12.60, Fairly Valued between -2.17 and -12.60, Overvalued between -2.17 and 3.04, and Strongly Overvalued above 3.04. The current Forward EV/EBITDA of -0.30 falls within the Overvalued range.
-0.31
EV/EBIT
Rocket Pharmaceuticals Inc. (RCKT) has a current EV/EBIT of -0.31. The 5-year average EV/EBIT is -6.50. The thresholds are as follows: Strongly Undervalued below -16.00, Undervalued between -16.00 and -11.25, Fairly Valued between -1.75 and -11.25, Overvalued between -1.75 and 3.00, and Strongly Overvalued above 3.00. The current Forward EV/EBIT of -0.31 falls within the Overvalued range.
438.28
PS
Rocket Pharmaceuticals Inc. (RCKT) has a current PS of 438.28. The 5-year average PS is 723.07. The thresholds are as follows: Strongly Undervalued below -4152.67, Undervalued between -4152.67 and -1714.80, Fairly Valued between 3160.93 and -1714.80, Overvalued between 3160.93 and 5598.80, and Strongly Overvalued above 5598.80. The current Forward PS of 438.28 falls within the Historic Trend Line -Fairly Valued range.
-4.96
P/OCF
Rocket Pharmaceuticals Inc. (RCKT) has a current P/OCF of -4.96. The 5-year average P/OCF is -10.36. The thresholds are as follows: Strongly Undervalued below -22.41, Undervalued between -22.41 and -16.38, Fairly Valued between -4.33 and -16.38, Overvalued between -4.33 and 1.69, and Strongly Overvalued above 1.69. The current Forward P/OCF of -4.96 falls within the Historic Trend Line -Fairly Valued range.
-2.21
P/FCF
Rocket Pharmaceuticals Inc. (RCKT) has a current P/FCF of -2.21. The 5-year average P/FCF is -9.82. The thresholds are as follows: Strongly Undervalued below -22.23, Undervalued between -22.23 and -16.03, Fairly Valued between -3.62 and -16.03, Overvalued between -3.62 and 2.59, and Strongly Overvalued above 2.59. The current Forward P/FCF of -2.21 falls within the Overvalued range.
Rocket Pharmaceuticals Inc (RCKT) has a current Price-to-Book (P/B) ratio of 0.89. Compared to its 3-year average P/B ratio of 3.50 , the current P/B ratio is approximately -74.67% higher. Relative to its 5-year average P/B ratio of 3.96, the current P/B ratio is about -77.63% higher. Rocket Pharmaceuticals Inc (RCKT) has a Forward Free Cash Flow (FCF) yield of approximately -65.42%. Compared to its 3-year average FCF yield of -17.48%, the current FCF yield is approximately 274.30% lower. Relative to its 5-year average FCF yield of -13.69% , the current FCF yield is about 377.70% lower.
0.89
P/B
Median3y
3.50
Median5y
3.96
-65.42
FCF Yield
Median3y
-17.48
Median5y
-13.69
Competitors Valuation Multiple
The average P/S ratio for RCKT's competitors is 74.01, providing a benchmark for relative valuation. Rocket Pharmaceuticals Inc Corp (RCKT) exhibits a P/S ratio of 438.28, which is 492.15% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RCKT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of RCKT in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Rocket Pharmaceuticals Inc (RCKT) currently overvalued or undervalued?
What is Rocket Pharmaceuticals Inc (RCKT) fair value?
How does RCKT's valuation metrics compare to the industry average?
What is the current P/B ratio for Rocket Pharmaceuticals Inc (RCKT) as of Aug 14 2025?
What is the current FCF Yield for Rocket Pharmaceuticals Inc (RCKT) as of Aug 14 2025?
What is the current Forward P/E ratio for Rocket Pharmaceuticals Inc (RCKT) as of Aug 14 2025?